Filing Flows › Profound Medical (PROF) › Q3 2025
Profound Medical (PROF) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Profound Medical (PROF) reported revenue of $5.3M for the third quarter 2025 (Q3 2025), +87% from a year earlier and +139% from the quarter before. Operating margin was -168.5%, net loss $8.0M (150.8% of revenue).
Profound Medical, Q3 2025: revenue $5.3M (+87% year over year), operating margin -168.5%, net loss $8.0M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.3M | +139% | +87% |
| Operating profit | −$8.9M | — | — |
| Net earnings | −$8.0M | — | — |
| Operating cash flow | −$9.6M | — | — |
What changed
Revenue was $5.3M in Q3 2025, up 87% year over year and up 139% from the previous quarter. Recurring - non-capital was the largest line at 77% of revenue. Recurring - non-capital added $1.4M year over year (up 53%), 58% of the total change.
Gross margin was 74.3%, up 11.2 points from a year earlier. Operating costs exceeded revenue by $8.9M, an operating margin of -168.5%. Operating expenses grew 19% against revenue growth of 87%. The fastest-growing cost line was Research & development (+30%). The quarter ended with a net loss of $8.0M, narrower than the previous quarter's $15.7M loss.
Operating cash flow was −$9.6M. Non-cash charges added back $147K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $3.5M.
Questions
What was Profound Medical's revenue in the third quarter 2025?
Profound Medical (PROF) reported revenue of $5.3M for the third quarter 2025 (Q3 2025), +87% from a year earlier and +139% from the quarter before.
Was Profound Medical profitable in the third quarter 2025?
Operating loss was $8.9M (-168.5% of revenue) and net loss $8.0M.
Source: Profound Medical 10-Q on SEC EDGAR.